Crispr Therapeutics (NASDAQ:CRSP) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday, November 30th, BidAskClub reports.
A number of other brokerages have also recently issued reports on CRSP. Roth Capital increased their price objective on shares of Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Goldman Sachs Group increased their price objective on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. ValuEngine raised shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Finally, Zacks Investment Research cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $69.54.
CRSP stock traded up $0.97 during midday trading on Friday, reaching $66.33. 920,983 shares of the company’s stock traded hands, compared to its average volume of 713,132. The stock’s 50-day moving average is $60.48 and its 200 day moving average is $48.87. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The stock has a market cap of $3.61 billion, a P/E ratio of -19.28 and a beta of 3.30. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. As a group, research analysts expect that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total value of $465,000.00. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at approximately $465,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock valued at $3,620,760 in the last 90 days. Company insiders own 21.40% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in CRSP. NEXT Financial Group Inc lifted its holdings in shares of Crispr Therapeutics by 915.0% in the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares during the last quarter. Benjamin Edwards Inc. increased its stake in Crispr Therapeutics by 96.4% in the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after buying an additional 268 shares during the period. Coastal Investment Advisors Inc. purchased a new position in Crispr Therapeutics in the 3rd quarter worth about $26,000. US Bancorp DE increased its stake in Crispr Therapeutics by 553.7% in the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after buying an additional 526 shares during the period. Finally, BSW Wealth Partners purchased a new position in Crispr Therapeutics in the 2nd quarter worth about $39,000. Hedge funds and other institutional investors own 49.82% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Average Daily Trade Volume – ADTV
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.